CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Anti-programed cell death 1 checkpoint inhibitors have recently demonstrated effectiveness against metastatic cancers including urothelial carcinoma.

Aims

To identify biomarkers/factors that correlate with the clinical response in advanced bladder cancer patients who received immune checkpoint inhibitor treatment.

Methods and results

We investigated tumors from 18 bladder cancer patients who had received anti-programed cell death 1 (pembrolizumab) or anti-programmed death-ligand 1 therapy (atezolizumab or durvalumab) and performed exome analysis, T-cell receptor sequencing of the tumor-infiltrating lymphocytes (TILs), and immunohistochemical analysis of CD8 and programmed death-ligand 1 in cancer tissues. Immunohistochemical analysis of bladder cancer tissu

SUBMITTER: Deng B 

PROVIDER: S-EPMC7941587 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature